CGEN - Compugen Ltd.
| Previous Close | 3.3000 |
| Open | 3.2500 |
| Bid | 3.26 x 900 |
| Ask | 3.29 x 800 |
| Day's Range | 3.2500 - 3.2900 |
| 52 Week Range | 2.3500 - 5.0000 |
| Volume | 46,342 |
| Avg. Volume | 212,158 |
| Market Cap | 185.89M |
| Beta (3Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.42 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
- GlobeNewswire•17 days ago
New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•27 days ago
Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy
HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.
- Zacks•last month
Compugen (CGEN) Reports Q3 Loss
Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Compugen: 3Q Earnings Snapshot
The Holon, Israel-based company said it had a loss of 5 cents per share. The drug developer posted revenue of $7.8 million in the period. The company's shares closed at $3.08. A year ago, they were trading ...
- PR Newswire•last month
Compugen Reports Third Quarter 2018 Results
HOLON, Israel , Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...
- Zacks•last month
Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?
Compugen has been struggling lately, but the selling pressure may be coming to an end soon.
- PR Newswire•2 months ago
Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET
HOLON, Israel , Oct. 24, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...
- Benzinga•2 months ago
Don't Fixate On Market Woes, Just Make Your Trades
Beyond my recent losses, October has actually been a strong month for me, although some in the chat are wondering how the recent market-wide selloff is affecting day traders. It was a fairly typical day for me, I was up, then down, then up again. Two of the top stocks to appear on my premarket scanner on Thursday, Spherix Inc. (NASDAQ: SPEX) and Compugen Ltd. (NASDAQ: CGEN), both collapsed on the opening bell.
- Zacks•2 months ago
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
- Zacks•2 months ago
Bristol-Myers Inks Deal and Invests $12 Million in Compugen
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
- MarketWatch•2 months ago
Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake
Shares of Compugen Ltd. shot up 17% in premarket trade Thursday, after Bristol-Myers Squibb Co. said it will make a $12 million equity investment as part of a collaboration on a cancer treatment. As part of the agreement, Bristol-Myers will buy about 2.4 million shares at $4.95 a share, which is 52% above Wednesday's closing price of $3.25. The companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's investigational anti-PVRIG antibody, COM701, in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors. Bristol-Myers' stock fell 1.3% ahead of the open. Year to date, Compugen's stock has soared 30% through Wednesday, while Bristol-Myers shares have slipped 0.8% and the S&P 500 has gained 4.2%.
- Reuters•2 months ago
Bristol-Myers to invest in Compugen, collaborate in clinical trials
Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours. The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo. In conjunction with the collaboration, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares - equal to a 4.1 percent stake - at $4.95 each.
- PR Newswire•2 months ago
Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
NEW YORK and HOLON, Israel , Oct. 11, 2018 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration ...
- Business Wire•2 months ago
Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Bristol-Myers Squibb Company and Compugen today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo , in patients with advanced solid tumors.
- PR Newswire•3 months ago
Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial
HOLON, Israel, Sept. 20, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein, in patients with advanced solid tumors. Under the terms of the collaboration and license agreement, Compugen is entitled to a milestone payment of $7.8 million at first patient dosing.
- Simply Wall St.•3 months ago
Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?
Anyone researching Compugen Ltd (NASDAQ:CGEN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there areRead More...
- PR Newswire•3 months ago
Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial
HOLON, Israel, Sept. 7, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG. PVRIG is a novel immune checkpoint identified by Compugen using its computational discovery capabilities. "Dosing the first patient with COM701, a first-in-class drug opportunity targeting a novel immune checkpoint we identified with our computational predictive platform, is a landmark event for us.
- PR Newswire•3 months ago
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
HOLON, Israel, Sept. 5, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Jean-Pierre Bizzari, M.D., formerly Executive Vice President and Global Head of Oncology at Celgene Corporation, to its Board of Directors. "I am delighted to welcome Jean-Pierre to Compugen's Board," said Paul Sekhri, Chairman of the Board. "I am confident that his extensive experience in oncology drug development will prove invaluable to Compugen.
- Associated Press•4 months ago
Compugen: 2Q Earnings Snapshot
The Holon, Israel-based company said it had a loss of 19 cents per share. The company's shares closed at $3.15. A year ago, they were trading at $4.05. _____ This story was generated by Automated Insights ...
- PR Newswire•4 months ago
Compugen Reports Second Quarter 2018 Results
Preparations for first patient dosing on track to take place in early fall HOLON, ISRAEL , Aug 1, 2018 /PRNewswire/ -- Compugen Ltd. ( Nasdaq: CGEN ), a clinical-stage cancer immunotherapy company and ...
- ACCESSWIRE•4 months ago
Compugen Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:30 AM Eastern Time. To listen ...
- PR Newswire•5 months ago
Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET
HOLON, Israel , July 18, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...
- Benzinga•5 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...
- PR Newswire•5 months ago
Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254
HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN) (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, was informed that the U.S. Food and Drug Administration (FDA) has cleared Bayer AG's investigational new drug (IND) application for BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein in patients with advanced solid tumors. ILDR2 is a novel immune checkpoint discovered by Compugen through its predictive computational capabilities, which enable the discovery of new drug targets and biological pathways.
- PR Newswire•5 months ago
Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its investigational new drug (IND) application for COM701, a first-in-class immuno-oncology therapeutic antibody targeting PVRIG in patients with advanced solid tumors, and informed the Company it may initiate the clinical study. "Today is a significant milestone for Compugen, having received clearance from the FDA to advance our lead immuno-oncology program into the clinic. COM701 is a first-in-class drug opportunity that was developed by Compugen from discovery of the drug target by computer prediction through preclinical development, to IND clearance," stated Anat Cohen-Dayag, PhD, President and CEO of Compugen.
